Advertisement

Topics

Shortening Dual Antiplatelet Therapy Ups MI Risk in ACS

12:55 EDT 14 Mar 2018 | Medscape

Although the SMART-DATE trial met its noninferiority composite endpoint, increased MI with shorter treatment led to the conclusion that 12 months or longer of DAPT should remain standard of care.
Medscape Medical News

Original Article: Shortening Dual Antiplatelet Therapy Ups MI Risk in ACS

NEXT ARTICLE

More From BioPortfolio on "Shortening Dual Antiplatelet Therapy Ups MI Risk in ACS"

Advertisement
Quick Search
Advertisement
Advertisement